Subscribe to our newsletter

VIDEO: Harrold reviews study on rituximab to treat RA

CorEvitas is now part of Thermo Fisher Scientific. Read More.

In this video interview, Dr. Leslie Harrold discussed her presentation regarding the impact of Rituxan on PROs in patients with RA. Dr. Harrold was quoted as saying, “What we did was we identified patients who were starting rituximab and looked at how they did at one year out using patient-reported outcomes.” Dr. Harrold concluded by saying that, “This data can be used to engage with patients, so as patients consider treatments and say, ‘How can this help someone like me?’ You can provide this information and help guide that conversation. It gives more information to help physicians and patients together make that decision.”

Link to the full article click here.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Leslie R. Harrold, MD, MPH, associate professor in the Department of Orthopedics and Physical Rehabilitation at the University of Massachusetts Medical School, reviewed results of a study in which rituximab improved patient-reported outcomes for patients with rheumatoid arthritis.

The study provides more information to physicians about patients who initiated rituximab after prior exposure to one or more anti-tumor necrosis factor inhibitors. She said the data can be used to assure patients who are considering rituximab, but have received multiple prior TNF inhibitors.